THE European Medicines Agency's (EMA) medicines committee has recommended granting an extension of the indication for the Nuvaxovid COVID-19 vaccine for use in adolescents aged 12-17 years.
The Novavax-developed immunisation is already approved in Europe for use in adults aged 18 and above.
The use of the vaccine in adolescents is the same as in adults, with two intramuscular injections given three weeks apart, the EMA said.
A study including over 2,200 children is being carried out in accordance with the vaccine's paediatric investigation plan.
The above article was sent to subscribers in Pharmacy Daily's issue from 24 Jun 22
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 Jun 22
